Tom Lillie

Tom Lillie has extensive work experience in the pharmaceutical industry. Tom is currently serving as the Chief Medical Officer at Grey Wolf Therapeutics since May 2023. Prior to this, they held the same position at Akamis Bio from January 2023 to present, and from January 2020 to January 2023.

Before joining Akamis Bio, Tom worked at MSD, where they held the positions of Vice President, Head of Oncology Global Medical Affairs from April 2018 to December 2019, and Vice President, Head of European Clinical Development from February 2016 to December 2019.

Prior to their time at MSD, Tom worked at Amgen, serving as Therapeutic Area Head, Oncology from September 2008 to January 2016. Tom also held the roles of Global Development Leader, Aranesp from August 2005 to August 2008, Medical Affairs Director, denosumab from January 2005 to August 2005, and Oncology Medical Leader from August 2002 to December 2004.

Tom began their career at Aventis as a Medical Affairs Manager from 2000 to 2003.

Tom Lillie began their education in 1986 at the University of Oxford, where they pursued a BA (hons) degree in Medicine. After completing their undergraduate studies in 1989, they enrolled at UCL for their PhD in Cell biology, 2nd messengers, and G-proteins. Tom Lillie then returned to UCL in 1992 to obtain their MD degree in Medicine, which they completed in 1995.